## AMENDMENT TO THE CLAIMS

## **Listing of Claims**

The following listing of claims replace all previous listings or versions thereof:

- 1. (Previously presented) A method of protecting a cell from organophosphate toxin comprising:
  - (a) providing an expression cassette comprising a promoter active in said cell and a gene encoding PON1 under the control of said promoter; and
  - (b) transferring said expression cassette into said cell under conditions permitting expression of PON1;

wherein said expression cassette expresses PON1 in said cell, resulting in detoxificiation of said organophosphate toxin.

- 2. (Withdrawn) The method of claim 1, wherein PON1 is PON1 type Q.
- 3. (Original) The method of claim 1, wherein PON1 is PON1 type R.
- 4. (Original) The method of claim 1, wherein said cell expresses PON1 type Q.
- 5. (Original) The method of claim 1, wherein said cell expresses PON1 type R.
- 6-8. (Canceled)
- 9. (Original) The method of claim 1, wherein said expression cassette further comprises a polyadenylation signal.

- 10. (Original) The method of claim 1, wherein said expression cassette is further comprised within a vector.
- 11. (Original) The method of claim 10, wherein said vector is a viral vector.
- 12. (Original) The method of claim 11, wherein said viral vector is a herpesviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a polyoma viral vector, and a vaccinia viral vector.
- 13. (Original) The method of claim 11, wherein said viral vector is an adenoviral vector.
- 14. (Original) The method of claim 1, wherein said promoter is a constitutive promoter.
- 15. (Original) The method of claim 1, wherein said promoter is an inducible promoter.
- 16. (Original) The method of claim 1, wherein said promoter is a tissue specific promoter.
- 17. (Original) The method of claim 4, wherein said expression cassette increases PON1 type Q expression by about 10-fold.
- 18. (Original) The method of claim 5, wherein said expression cassette increases PON1 type

  R expression by about 10-fold.
- 19. (Original) The method of claim 1, wherein said cell is a liver cell.
- 20. (Original) The method of claim 1, wherein said cell expresses low levels of PON1 typeQ or R as compared to the general population.
- 21. (Previously presented) A method of protecting a subject from an organophosphate toxin comprising:

- (a) providing an expression cassette comprising
  - (i) a promoter active in cells of said subject,
  - (ii) a gene encoding PON1 under the control of said promoter; and
- (b) administering to said subject said expression cassette under conditions permitting expression of PON1;

wherein said expression cassette expresses PON1 in said cell, resulting in detoxificiation of said organophosphate toxin.

- 22. (Previously presented) The method of claim 21, wherein PON1 is PON1 type Q.
- 23. (Previously presented) The method of claim 21, wherein PON1 is PON1 type R.
- 24. (Previously presented) The method of claim 21, wherein said viral vector is a herpesviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a polyoma viral vector, and a vaccinia viral vector.
- 25. (Original) The method of claim 21, wherein administering comprises intravenously or intraarterially.

26-35. (Canceled)